Robert Welp > Hogan Lovells US LLP > Northern Virginia, United States > Lawyer Profile

Hogan Lovells US LLP
8350 BROAD STREET
17TH FLOOR
MCLEAN, VA 22102
VIRGINIA
United States

Work Department

Corporate Transactional & Private Equity - Northern Virginia

Position

Partner

Career

Consistently recognized for his outstanding work in merger and acquisition transactions, Robert Welp serves leading private equity firms and private companies in their transactions in the U.S. and throughout the world.

Robert is the head of private equity for the Americas at Hogan Lovells. He focuses his practice primarily on private equity-sponsored companies, funds, and their investments in energy, life sciences and health care, technology, government services, consumer, and other regulated sectors. Robert consistently advises funds and their portfolio companies regarding their acquisition and growth strategies. He also has deep experience in restructuring, recapitalization, and reorganization transactions throughout significant market inflections.

Memberships

Bar Associations – Texas, Washington, D.C. and Virginia

Education

J.D., The University of Texas School of Law, 1992

B.A., Southern Methodist University, 1989

Lawyer Rankings

United States > M&A/corporate and commercial > Venture capital and emerging companies

Hogan Lovells US LLP has strong credentials in the venture fund space and is especially active on the investor side, representing a broad range of institutions, funds and family offices. The team also has good experience on the company side, and assisted Walmart on a joint venture with Ribbit Capital to launch a new fintech startup. The overall breadth of the firm’s offering is enhanced by its geographic reach, with a combination of teams in key US hubs such as Silicon Valley and Washington DC, as well as Europe and Asia. The private equity and funds group is led by Robert Welp  out of Northern Virginia. Key partners include Mark Heimlich in Denver, Mahvesh Qureshi and Kevin Clayton  in Washington DC, and Houston’s Andrew Strong who co-leads the firm’s emerging companies and investor group and has a strong track record on the life sciences and biotech front.